2026-07-22T03:36:54Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/255092025-12-18T12:55:57Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Whittaker, Robert author Dias, Joana Gomes author Ramliden, Miriam author Ködmön, Csaba author Economopoulou, Assimoula author Beer, Netta author Pastore Celentano, Lucia author ECDC network members for invasive meningococcal disease author Cano-Portero, Rosa author Abad, Raquel author 2017-04-11 Background: Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology of IMD in EU/EEA countries during 2004-2014 to monitor serogroup- and age-specific trends, and compare country trends by the period of meningococcal C conjugate (MCC) vaccine introduction. Methods: We analysed IMD surveillance data by age, gender, serogroup, country and outcome. We estimated the percentage change in annual notification rate (NR), using linear regression analysis of the log of the annual NR. We grouped countries by the year they introduced MCC vaccination into their routine immunisation programmes. Results: The overall NR was 0.9/100 000 population, and decreased 6.6% (95%CI: -8.0%;-5.1%) annually. Infants had the highest NR (16.0/100 000), and there were decreasing trends in all age groups <50years. Serogroup B (SgB) caused 74% of all cases, and the majority of cases in all age groups. There were decreasing trends in SgB and serogroup C (SgC) and an increasing trend in serogroup Y. Countries that introduced MCC vaccination before, and between 2004 and 2014, had decreasing trends in NR of SgC, but not countries without routine MCC vaccination. Conclusions: Our findings support evidence that routine MCC vaccination was the driving force behind the decreasing SgC trend. Vaccinating against SgB in the first year of life could help reduce the burden of IMD due to this serogroup. Changing serogroup-specific NR trends highlight the need for high-quality surveillance data to accurately assess the changing epidemiology of IMD, the effectiveness and impact of implemented vaccines, and the need for future vaccines. Vaccine. 2017 Apr 11;35(16):2034-2041. 10.1016/j.vaccine.2017.03.007 1873-2518 0264-410X Vaccine 28314560 https://hdl.handle.net/20.500.12105/25509 Epidemiology Europe Invasive meningococcal disease (IMD) Neisseria meningitidis Serogroup Surveillance The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014